Page last updated: 2024-11-02

pioglitazone and Anti-Glomerular Basement Membrane Disease

pioglitazone has been researched along with Anti-Glomerular Basement Membrane Disease in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Anti-Glomerular Basement Membrane Disease: An autoimmune disease of the KIDNEY and the LUNG. It is characterized by the presence of circulating autoantibodies targeting the epitopes in the non-collagenous domains of COLLAGEN TYPE IV in the basement membranes of kidney glomeruli (KIDNEY GLOMERULUS) and lung alveoli (PULMONARY ALVEOLI), and the subsequent destruction of these basement membranes. Clinical features include pulmonary alveolar hemorrhage and glomerulonephritis.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Haraguchi, K1
Shimura, H1
Onaya, T1

Other Studies

1 other study available for pioglitazone and Anti-Glomerular Basement Membrane Disease

ArticleYear
Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor (PPAR)gamma activators.
    Clinical and experimental nephrology, 2003, Volume: 7, Issue:1

    Topics: Animals; Anti-Glomerular Basement Membrane Disease; Antibodies; Autoantibodies; CD8-Positive T-Lymph

2003